Kornimate/medical-research-clean huggingface dataset:
study on functional electrical stimulation (fes) cycling following spinal cord injury

Conditions: Spinal Cord Injury

Summary: this research is being done to study the effect of functional electrical stimulation (fes) cycling on factors in blood and spinal cord in people with spinal cord injury (sci).

fes cycling is a method of applying low level electrical currents to the leg and buttock muscles to cause the weakened or paralyzed muscles to contract and produce a cycling motion of the legs. the fes cycling in this study will be done through a device called the rt300-sl cycle ergometer. although this device has been cleared by the food and drug administration (fda) for use by individuals with spinal cord injury, we are trying to find out the best way to use it in order to obtain the greatest benefits in an attempt to improve functional recovery.

Eligibility criteria:
inclusion criteria: * history of traumatic spinal cord injury sustained at least 6 months prior * complete spinal cord injury at any level american spinal injury association (asia) impairment scale a * no use of functional electrical stimulation within 3 months * medically stable, with no recent (1 month or less) inpatient admission for acute medical or surgical issues * legally able to make own health care decisions exclusion criteria: * cardiovascular disease as defined by previous myocardial infarction, unstable angina, requirement for anti platelet agents, congestive heart failure, or stroke, history of arrhythmia with hemodynamic instability * uncontrolled hypertension (resting systolic blood pressure (bp) \>160mmhg or diastolic bp \>100mmhg consistently) * concurrent lower motor neuron disease such as peripheral neuropathy that would exclude lower extremity electrical excitability * unstable long bone fractures of the lower extremities * subjects who are unwilling to agree to two (2) csf examinations (lumbar punctures) * presence of cardiac pacemaker and/or defibrillator * presence of cancer * history of epileptic seizures * subjects having a stage 2 or greater sacral decubitus ulcer * women who are pregnant * active drug or alcohol use or dependence

Keywords: spinal cord injury functional electrical stimulation rehabilitation growth factors cytokines
iv dexketoprofen vs placebo in migranie attack

Conditions: Migraine

Summary: h0 hypothesis: iv dexketoprofen is equivalent to placebo in ceasing migraine attack in emergency department. h1 hypothesis: iv dexketoprofen is not equivalent (superior) to placebo in ceasing migraine attack in emergency department.

migraine attack is one of the most leading causes presentations to emergency department. patients with migraine attack seek urgent care to cease their pain. there are so many interventions defined in the medical literature that can be used in migraine attacks. however, as a iv drug, dexketoprofen; little known whether iv dexketoprofen is superior to placebo or not. in the present study we aimed to determine the effects of iv dexketoprofen in migraine attack in emergency department.

Eligibility criteria:
inclusion criteria: * patients presented with headache who diagnosed as migraine attack according to the international headache society exclusion criteria: * denied to give inform concent, illiterate patients, chronic renal failure, taking nsaids during the last six hours, pregnancy

Keywords: migraine, emergency department, dexketoprofen, placebo
"cryptogenic stroke and atrial fibrillation detection through implantable loop recorder (ilr)"

Conditions: Atrial Fibrillation; Stroke

Summary: study type: prospective, national , multicenter, and observational study. objective: to assess the incidence of af in patients with cryptogenic stroke who have implanted an af detection device during a period of 2 years. device: reveal xt 9529 (sqdm) sample size and study duration: 100 patients enrolled which will be followed during a period of 2 years.

observational study in patients with cryptogenic stroke (toast criteria) and with an implanted ekg loop recorder, with the primary objective of knowing the atrial fibrillation incidence in this population

Eligibility criteria:
inclusion criteria: * all patients included must meet one of these two conditions: * patient presenting with an episode of transient ischemic attack (tia) of cryptogenic origin with neurological symptoms of less than 24h of evolution and negative neuroimaging. * first episode of ischaemic stroke with cryptogenic etiology following toast criteria * all patients must meet all of the following: * the patient has been implanted an ilr within 30 days after qualifying event * age between 45-85 years * no stenosis \>50% in any arterial vessel corresponding to the affected territory * normal echocardiography * normal 24 hours ekg holter recording * absence of patent foramen ovale through transcranial doppler (or transesophageal echocardiography) * acceptance and signature of patient informed consent. exclusion criteria: * all patients included cannot meet any of the following conditions: * recurrent stroke or tia * stroke or tia with determined etiology according to toast criteria. * anticoagulation indication at the time of enrollment in the study. * total contraindication for anticoagulation therapy * atrial fibrillation detection prior to enrollment * severe cognitive impairment or dementia * patient unable to be followed up * patients enrolled in another clinical trial * patients with life expectancy of less than 1 year * pregnancy

Keywords: atrial fibrillation cryptogenic stroke implantable loop recorder
endoscopic therapy or surgery for early colon cancer

Conditions: Colon Cancer

Summary: the trial is a randomized head-to-head comparison of the benefits, harms and burdens of endoscopic full-thickness resection (eftr), a novel, minimally invasive endoscopic treatment modality, for early colon cancer as compared to standard-of-care surgery.


Eligibility criteria:
inclusion criteria: * newly diagnosed biopsy-confirmed colon cancer (adenocarcinoma) with macroscopic suspicion of submucosal invasion considered removable by eftr as deemed by the local multidisciplinary team (mdt) at the participating center * size ≤20 mm in diameter as deemed by the colonoscopist * no presence of histopathological high-risk features in biopsy (high grade tumor growth, budding grade 2 or 3, or lymphovascular invasion) * patient eligible for surgical removal as deemed by the local mdt at the participating center * endoscopic images or video of the tumor * no sign of disease beyond t2n0m0 on pre-treatment imaging, biopsy sampling, and radiographic and clinical evaluation * no contraindication for any of the two treatment arms * written informed consent * no prior or synchronous crc * no other malignancy which is not cured * no more than 10 adenomas or serrated polyps * no genetic cancer syndrome (adenomatous or serrated polyposis syndrome; lynch or lynch-like syndrome) * no inflammatory bowel disease
aripiprazole once-monthly versus paliperidone palmitate in adult patients with schizophrenia

Conditions: Schizophrenia

Summary: to assess the effectiveness of aripiprazole once-monthly in the maintenance treatment of patients with a diagnosis of schizophrenia as defined by the diagnostic and statistical manual of mental disorders, 4th edition, text revision (dsm-iv-tr®), in a naturalistic care setting by comparing it to an existing long-acting antipsychotic, paliperidone palmitate.


Eligibility criteria:
main inclusion criteria: * the patient has schizophrenia, diagnosed according to dsm-iv-tr®. * the patient has a cgi-s score from mildly ill to markedly ill at the screening and baseline visit(s). * the patient is in need of a change in the current antipsychotic treatment and in the judgement of the investigator the patient would benefit from an extended treatment with a once-monthly formulation. * the patient agrees to protocol-defined use of effective contraception. main exclusion criteria: * the patient has any current psychiatric disorder or axis i disorder (dsm-iv® criteria) other than schizophrenia established as the primary diagnosis. * the patient is experiencing acute exacerbation of psychotic symptoms at the screening visit or between the screening and baseline visits. * the patient in the investigator's judgment has shown significant intolerance and/or lack of efficacy to oral aripiprazole, paliperidone or risperidone. * the patient is at significant risk of harming himself/herself or others according to the investigator's judgement or according to columbia-suicide severity rating scale (c-ssrs). * the patient has a history of neuroleptic malignant syndrome. * the patient has or has had significant medical condition that would expose him or her to an undue risk of a significant adverse event or interfere with assessments of safety or efficacy during the course of the study including, but not limited to neurological, hepatic, renal, metabolic, haematological, immunological, gastrointestinal, pulmonary, or cardiovascular disorders. * the patient has a disease or takes medication that could, in the investigator's opinion, interfere with the assessments of safety, tolerability, or efficacy, or interfere with the conduct or interpretation of the study. * the patient is, in the investigator's opinion, unlikely to comply with the protocol or is unsuitable for any reason.
acupuncture for pain and sleep disturbance in knee osteoarthritis

Conditions: Sleep; Pain

Summary: the hypotheses of this study are: in the older population with knee oa, * when acupoints are chosen for both sleep and pain, there are additive effects on sleep improvement and pain relief (i.e. no interaction). * main effects of acupuncture on sleep improvement and pain relief are anticipated when acupoints are separately targeted for sleep and for pain, respectively.


Eligibility criteria:
inclusion criteria: 1. patients with knee osteoarthritis, diagnosed by the acr clinical diagnosis criteria for idiopathic oa, with at least kellgren and lawrence grading ii and above. and, 2. present with knee pain at least half of the time. and, 3. complain of sleep disturbances associated with knee oa, with pittsburgh sleep quality index \> 5 \[36\]. exclusion criteria: 1. patients with diagnosis of obstructive sleep apnea (osa). or, 2. patients with dense hemiplegia secondary to cerebrovascular accident. or, 3. nyha class iii - patients with heart failure condition limited by minimal activity. or, 4. severe copd with shortness of breath at minimal exertion. or, 5. peripheral vascular disease with severe claudication. or, 6. dementia with mini mental status exam score of 20 or less. or, 7. patients who received knee intra-articular corticosteroid injection within 4 weeks prior to the study or who received acupuncture treatment within 6 months. or, 8. unwilling to come off narcotic pain medication. or, 9. history of bleeding diathesis or currently on anticoagulation. or, 10. patients currently engaged in medical legal cases related to oa or disability.
the hiv testing trends and outcomes at a johannesburg trauma icu unit

Conditions: Outcome, Fatal

Summary: a retrospective observational study on the hiv testing trend and outcomes in a trauma population admitted to a critical care unit for care.

trauma icu admission of 18 years and older were enrolled in the study. the hiv status was further divided into hiv-positive, hiv-negative, and hiv-unknown subgroups. the gender, ages, mechanism of injury, injuries sustained, iss, physiological data, septic-related complications, and in-hospital mortality were noted and further analyzed. descriptive statistics were utilised using stata version 15, and a p-value of \<0.05 was considered statistically significant.

Eligibility criteria:
inclusion criteria: trauma patients admitted to a trauma icu at cmjah - exclusion criteria: those under the age of 18 or with incomplete data -
gene therapy in treating patients with cancer of the liver

Conditions: Liver Cancer

Summary: phase i trial to study the effectiveness of gene therapy with the p53 gene in treating patients who have cancer of the liver that cannot be surgically removed. inserting the p53 gene into a person's tumor may improve the body's ability to fight liver cancer.

objectives: i. determine the safety of adenovirus p53 construct (adeno-p53) in patients with hepatocellular carcinoma. ii. investigate the potential effects of intralesional adeno-p53 given by monthly percutaneous injections in these patients. outline: this is a dose escalation, multicenter study. patients receive adenovirus p53 construct by percutaneous injection to a maximum of two lesions on day 1. treatment is repeated every 28 days for up to 6 courses. in the absence of dose-limiting toxicity (dlt) in the first cohort of 6 patients treated, subsequent cohorts of 6 patients each receive escalating doses of the drug on the same schedule. if dlt occurs in 2 of 6 patients at a given dose level, then dose escalation ceases and that dose is declared the maximum tolerated dose. study treatment may continue in the absence of disease progression and unacceptable adverse events.

Eligibility criteria:
disease characteristics: * histologically confirmed unresectable hepatocellular carcinoma (hcc) or highly suspicious for hcc based on ct scan and elevated alfafetoprotein * measurable disease by abdominal ct scan accessible (peripheral) lesions * no metastatic disease patient characteristics: * age: over 18 * performance status: ecog 0-2 * life expectancy: at least 12 weeks * platelet count at least 60,000/mm3 * absolute neutrophil count greater than 1,500/mm3 * prothrombin time of no greater than 16 seconds after administration of fresh frozen plasma * bilirubin no greater than 3.0 mg/dl * creatinine less than 1.5 mg/dl * child's class a or b cirrhosis eligible * no uncontrolled infection not pregnant or breast feeding * no unstable or severe intercurrent medical condition prior concurrent therapy: * at least 4 weeks since prior chemotherapy * at least 4 weeks since prior radiation therapy * no prior hepatic transplantation * no more than 1 prior systemic regimen for hepatocellular carcinoma allowed * no concurrent therapy with other investigational agents * no prior gene therapy * no prior intralesional therapy

Keywords: localized unresectable adult primary liver cancer adult primary hepatocellular carcinoma
impact of alpine dairy products on blood lipid levels

Conditions: Elevated Cholesterol

Summary: elevated blood lipid levels are one of the main risk factors for cardiovascular disease. to manage elevated blood lipid levels in otherwise healthy people at low risk of cardiovascular disease, lifestyle changes are recommended as the first treatment strategy. one of these changes concerns diet. clinical observations by general practitioners in alpine regions of switzerland have shown that consumption of dairy products produced from cows living and grazing at high altitudes can have a beneficial effect on blood lipid parameters. however, little clinical data is available on the effect of alpine dairy products on health-related markers. this pilot study aims to assess if replacing standard (non-alpine) dairy products by alpine dairy products in the daily diet among patients with elevated ldl-cholesterol levels could reduce the blood ldl-cholesterol levels.


Eligibility criteria:
inclusion criteria: * age ≥18 years old * elevated lipid levels, namely: fasting ldl-cholesterol \>3mmol/l and \</=5mmol/l * agreeing to eat 3 portions of dairy products daily (according to instructions) exclusion criteria: * eating less than two and more than six portions of dairy products daily * body weight change +/-5% of body weight in the last three months * secondary prevention treatment for cardiovascular disease * moderate, high or very high cardiovascular risk according to agla score * currently taking psck9-inhibitors, ezetimibe, statins, glucocorticoids * poorly controlled, severe chronic renal insufficiency, hypothyroidism, cholestasis, nephrotic syndrome, eating disorders, alcohol abuse, cushing syndrome * myocardial infarction, percutaneous coronary intervention or coronary artery bypass grafting in the previous 6 months * known lactose intolerance or dairy allergies * change of diet less than 2 months before intervention * pregnant or breastfeeding * incapacity of judgement * inability to speak and read german
effect of vitamin d supplementation on testosterone level in women with polycystic ovary syndrome

Conditions: PCOS; Vitamin D

Summary: the goal of this randomized, double blind, placebo-controlled clinical trial is to learn about, the effect of low dose vitamin d supplementation compares with placebo-controlled group on testosterone level in women with polycystic ovary syndrome. half of participants will receive vitamin d and metformin while other half placebo and metformin.

pcos poses a significant challenge to women's health and quality of life. pcos is a common heterogenous endocrine disorder in reproductive-aged women. pcos is characterized by the presence of polycystic ovaries, menstrual dysfunction, infertility and biochemical (elevated androgens) and clinical (hirsutism and/or acne) hyperandrogenism. hyperandrogenism and insulin resistance exacerbate one another in the development of pcos, research has suggested a potential link between vitamin d deficiency and the prevalence and severity of pcos. there is also evidence that vitamin d has a direct effect on the ovaries and adrenal glands, which are the primary sites of androgen production in women. vitamin d has been found to inhibit the synthesis of androgens in these glands, suggesting that it could potentially be used to manage hyperandrogenism in women with pcos. furthermore, studies have shown that vitamin d supplementation can reduce insulin resistance in women with pcos, which can subsequently lead to a decrease in the overproduction of androgens. may improves menstrual irregularities. in human ovarian tissue, vitamin d stimulation of oestrogen and progesterone production and lack of effect on testosterone production may be explained by the expression of the aromatase gene and augmentation of aromatase activity by vitamin d. serum 25oh-d level has been shown to be negatively correlated with serum androgen levels dheas, testosterone and hirsutism. assumption that vitamin d supplementation may also have a positive impact on serum testosterone levels. metformin is prescribed for reducing ir in pcos women. this is a double-blind, randomized placebo-controlled trial in pcos women who are receiving metformin therapy. the intervention group will receive vitamin d cholecalciferol (d3) 1000 i.u daily for 8 weeks, with the metformin as prescribed by the physician whereas control group will receive placebo with metformin during the study period. we will compare change of total testosterone, vitamin d level, fasting blood glucose, hirsutism, menstrual regularities and bmi, at the time of recruitment with after 8 weeks intervention in both the intervention and placebo controlled groups.

Eligibility criteria:
inclusion criteria: * diagnosed case of pcos age 18 years to 45 years exclusion criteria: * pregnancy, lactating women diagnosed case of diabetes mellitus, liver disease, heart disease, kidney stones and disease, tuberculosis, hyperparathyroidism patients receiving vitamin d, calcium supplementation within the last two months known hypersensitivity to vitamin d patients unwilling to participate or unwilling to give written consent

Keywords: pcos, vitamin d, testosterone
effect of need to void on gait speed in multiple sclerosis

Conditions: Multiple Sclerosis; Lower Urinary Tract Symptoms; Gait

Summary: multiple sclerosis causes demyelinating lesions, which can induce multiple symptoms. if motor disorders are the most visible disability, urinary disorders are frequent, with prevalence from 32 to 86%. the first ones are due to pyramidal, cerebellar or proprioceptive lesions. the seconds are due to specific lesion in inhibitor/activator encephalic centers, or interruption on medullary conduction. it seems to be evident that walk and urinary disorders are link, because of similar anatomic ways and control process. effect of bladder filling is well known on motoneuronal excitability. the effect of bladder filling on walk stay unknown, while medullary integration of these two functions is very close, in medullary cone. primary aim is to assess the effect of need to void on walk speed in multiple sclerosis with lower urinary tract symptoms. secondary aim is to identify clinical or urodynamic factor link with major walk impairment when patients need to void. patient with multiple sclerosis over 18 years old, consulting for lower urinary tract symptoms in a tertiary center are included. history and treatment, high, weigh, symptoms severity by usp score, cognitive impairment by mmse score and last urodynamic data are recorded. patient are asked to drink water until they feel a strong need to void, for which they would go to urinate at home. walk tests are realized in a specific place, with calm and no passage. a chair is placed at each end of the path. toilets are just next to the hall where they realize the tests. a 10 meters walk test is done during this condition, 3 times (only the intermediate 6 meters are recorded). they can take 30 seconds of rest between each try if necessary. one timed up and go is done. patient can use their habitual walking device. speed walk asking is comfortable for the two test. next, patient can urinate. 3 post void residual volume with portable echography are done, and the higher is recorded. patient achieve the same walk tests after urinate, in the same order. they must use the same walking device. primary outcome is mean gait recorded for 10 meters walk test. secondary outcome is time for timed up and go test. individual variability between the 3 10mwt in the two conditions will be study. influence of age, edss, severity of symptoms, mmse, detrusor overactivity on speed impairment will be study in secondary analysis.


Eligibility criteria:
inclusion criteria: * multiple sclerosis * follow in neuro-urology for lower urinary tract symtpoms * able to walk 50 meters without human assistance * able to hold on void during 3 minutes at least exclusion criteria: * actual urinary tract infection * relapse in the last week * mini mental state examination \< 10

Keywords: gait speed multiple sclerosis lower urinary tract symptoms overactive bladder
ischemia and reperfusion injury in the human: an observational study

Conditions: Ischemia

Summary: we, the researchers at lawson health research institute, propose to investigate the impact of surgical ischemia and reperfusion on skeletal muscle microcirculation using a hand-held microscope.

we propose to investigate the impact of surgical ischemia and reperfusion on skeletal muscle microcirculation using a hand-held microscope.

Eligibility criteria:
inclusion criteria: * patients undergoing femoral distal bypass procedures for chronic limb ischemia exclusion criteria: * any severe comorbid conditions (i.e., chronic obstructive pulmonary disease \[copd\])

Keywords: ischemic preconditioning microvascular perfusion inflammation ischemia and reperfusion chronic limb ischemia